Zynerba Pharmaceuticals (NASDAQ:ZYNE) – Stock analysts at Oppenheimer issued their Q2 2018 EPS estimates for shares of Zynerba Pharmaceuticals in a note issued to investors on Tuesday, March 13th, according to Zacks Investment Research. Oppenheimer analyst D. Archila expects that the company will post earnings of ($0.70) per share for the quarter. Oppenheimer currently has a “Hold” rating on the stock. Oppenheimer also issued estimates for Zynerba Pharmaceuticals’ Q3 2018 earnings at ($0.79) EPS, Q4 2018 earnings at ($0.85) EPS, FY2018 earnings at ($2.96) EPS, FY2019 earnings at ($2.21) EPS, FY2020 earnings at ($2.91) EPS, FY2021 earnings at ($2.70) EPS and FY2022 earnings at ($1.64) EPS.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last released its quarterly earnings data on Monday, March 12th. The company reported ($0.60) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.60). During the same quarter last year, the company earned ($0.71) earnings per share.
Other equities analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 price objective on the stock in a report on Thursday, March 15th. Seaport Global Securities reissued a “buy” rating on shares of Zynerba Pharmaceuticals in a research report on Tuesday, March 13th. HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, March 13th. Cantor Fitzgerald set a $20.00 target price on shares of Zynerba Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 12th. Finally, Ladenburg Thalmann assumed coverage on shares of Zynerba Pharmaceuticals in a research report on Monday, January 29th. They issued a “buy” rating and a $25.50 target price for the company. One research analyst has rated the stock with a sell rating, five have given a hold rating and eight have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $17.86.
Shares of NASDAQ:ZYNE traded down $0.31 on Friday, hitting $8.82. The company had a trading volume of 153,029 shares, compared to its average volume of 315,577. Zynerba Pharmaceuticals has a 1-year low of $5.42 and a 1-year high of $25.95. The company has a market cap of $123.82, a P/E ratio of -3.56 and a beta of 4.94.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Nationwide Fund Advisors bought a new stake in Zynerba Pharmaceuticals during the second quarter worth about $110,000. BlackRock Inc. lifted its position in Zynerba Pharmaceuticals by 1.1% during the fourth quarter. BlackRock Inc. now owns 678,697 shares of the company’s stock worth $8,497,000 after purchasing an additional 7,091 shares during the period. The Manufacturers Life Insurance Company bought a new stake in Zynerba Pharmaceuticals during the second quarter worth about $158,000. New York State Common Retirement Fund bought a new stake in Zynerba Pharmaceuticals during the second quarter worth about $207,000. Finally, Parametric Portfolio Associates LLC bought a new stake in Zynerba Pharmaceuticals during the second quarter worth about $223,000. 28.92% of the stock is owned by institutional investors and hedge funds.
In other news, major shareholder Michael Rapp acquired 10,000 shares of the business’s stock in a transaction that occurred on Thursday, March 22nd. The stock was acquired at an average price of $9.28 per share, with a total value of $92,800.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.91% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Research Analysts Issue Forecasts for Zynerba Pharmaceuticals’ Q2 2018 Earnings (ZYNE)” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/04/07/zynerba-pharmaceuticals-inc-to-post-q2-2018-earnings-of-0-70-per-share-oppenheimer-forecasts-zyne.html.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Get a free copy of the Zacks research report on Zynerba Pharmaceuticals (ZYNE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.